Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder
Authors:
- Javier Villacieros-ÁlvarezJVJavier Villacieros-Álvarez
- Maria SepulvedaMSMaria Sepulveda
- Adrián Valls-CarbóAVAdrián Valls-Carbó
- Nicolas FissoloNicolas Fissolo
- Alessandro DinotoADAlessandro Dinoto
- Victoria FernándezVFVictoria Fernández
- Andreu VilasecaAVAndreu Vilaseca
- Georgina ArrambideGAGeorgina Arrambide
- Lucia GutierrezLGLucia Gutierrez
- Mireia CastilloMCMireia Castillo
- Luca BolloLBLuca Bollo
- Carmen EspejoCECarmen Espejo
Open Access
- 1 September 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (5) , e200432
Abstract
To investigate whether CSF 14-3-3 protein levels discriminate aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) and the association of CSF 14-3-3 protein levels with clinical features in patients with AQP4-NMOSD. This was a multicentric retrospective cohort study of patients with AQP4-NMOSD, MOGAD, and MS, with available CSF samples. 14-3-3 protein levels were quantified using ELISA and compared between the 3 conditions. In patients with AQP4-NMOSD, the association between CSF 14-3-3 protein levels and disability outcomes was explored. A total of 134 patients were included (AQP4-NMOSD, n = 29; MOGAD, n = 43; MS, n = 62). Patients with AQP4-NMOSD had higher 14-3-3 protein levels (median [interquartile range] 4,441.37 [3,240.05-11526.41] arbitrary units (AU)/mL) compared with those with MS (3,169.86 [2,522.65-3,748.57], p = 0.001) and MOGAD (3,112.95 [2,367.37-3,889.43], p = 0.004). Patients with AQP4-NMOSD presenting with optic neuritis had lower 14-3-3 levels compared with those with other phenotypes (p < 0.001). In AQP4-NMOSD, 14-3-3 levels associated with Expanded Disability Status Scale (EDSS) at attack (β [95%CI] 0.33 [0.15-0.52], p = 0.003) and predicted final EDSS ≥ 6.0 (odds ratio 9.48 [1.69; 194.34]; p = 0.041) in patients with myelitis. The study suggests a potential role of CSF 14-3-3 protein levels as a biomarker of neuroaxonal damage in AQP4-NMOSD, because of its ability to correlate with disease severity and predict poor clinical recovery. This study provides Class IV evidence that in individuals presenting with acute myelitis, CSF 14-3-3 differentiates AQP4-NMOSD from MS or MOGAD with a sensitivity of 0.60 (0.30-0.80) and specificity of 0.95 (0.84-1.00).Keywords
This publication has 20 references indexed in Scilit:
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Inflammatory demyelinating diseases of the central nervous system2018
- Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies StatusMultiple Sclerosis Journal – Experimental, Translational and Clinical, 2017
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015
- High CSF neurofilament heavy chain levels in neuromyelitis opticaNeurology, 2007
- CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MSJournal of Neurology, 2004
- 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosisNeurology, 2001
- 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitisThe Lancet, 2000
- Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disordersAnnals of Neurology, 1999
- The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform EncephalopathiesNew England Journal of Medicine, 1996